MELD & PELD Calculators (Model for End-Stage Liver Disease & Pediatric End-Stage Liver Disease)
Use this clinical tool to calculate both adult and pediatric liver disease severity scores. These scoring systems estimate short-term mortality risks for patients with chronic liver disease and are used globally to prioritize organ allocation for liver transplantation.
MELD 3.0 is utilized for candidates aged 12 and older.
PELD-Cr (2023 Update) is utilized for pediatric candidates under 12 years of age.
Understanding MELD 3.0 (Ages 12+)
The Model for End-Stage Liver Disease (MELD) evaluates 90-day waitlist survival for adult candidates. The current standard, MELD 3.0, updates older iterations (like MELD-Na) by adding serum albumin and accounting for sex-based differences. Historically, females faced disadvantageous organ allocation because lower average baseline muscle mass resulted in lower creatinine levels despite similar degrees of renal impairment. MELD 3.0 corrects this disparity.
MELD 3.0 Required Clinical Variables:
Total Bilirubin (mg/dL): Measures hepatic excretory function.
International Normalized Ratio (INR): Evaluates hepatic synthetic function (clotting factor production).
Serum Creatinine (mg/dL): Captures renal function. Values are capped at 3.0 mg/dL, and default to 3.0 mg/dL if the patient received dialysis twice or continuous venovenous hemodialysis (CVVHD) for 24 hours within the preceding week.
Serum Sodium (mEq/L): Identifies dilutional hyponatremia, common in advanced portal hypertension. Values are bound between 125 and 137 mEq/L.
Serum Albumin (g/dL): Reflects hepatic protein synthesis capacity. Values are bound between 1.5 and 3.5 g/dL.
Biological Sex: Female sex adds an adjusted variable (+1.33 coefficient) to correct for creatinine underestimation.
Understanding PELD-Cr (Ages <12)
The Pediatric End-Stage Liver Disease (PELD) model accounts for the specific physiological demands and mortality predictors unique to children. The modern PELD-Cr score adopted by the Organ Procurement and Transplantation Network (OPTN) integrates serum creatinine alongside growth metrics to optimize survival predictions.
PELD-Cr Required Clinical Variables:
Total Bilirubin (mg/dL) & INR: Markers of hepatic clearance and synthesis.
Serum Albumin (g/dL): Indicators of severe protein synthesis deficits.
Serum Creatinine (mg/dL): Assesses pediatric renal health. If a child requires dialysis twice or 24 hours of CVVHD in the prior week, the system defaults the creatinine value to 1.3 mg/dL.
Growth Failure (Z-scores): Calculated using the child's height, weight, and age against standardized CDC growth charts. Severe growth restriction (the lowest value of the height or weight Z-scores) significantly increases the final score, reflecting the metabolic toll of pediatric liver failure.
Age at Listing: Younger age—specifically infancy (<1 year)—carries distinct historical waitlist mortality weighting.
Clinical Interpretation and Organ Allocation
Scores are calculated using logarithmic formulas, rounded to the nearest integer, and utilized dynamically by transplantation networks:
Range: MELD 3.0 ranges from 6 up to a maximum cap of 40. PELD-Cr outputs scores starting at a minimum of 6.
Urgency: Higher numbers correspond directly to decreased short-term survival probability. Organ allocation priorities are continuously updated based on these figures to ensure those with the highest medical urgency are offered matching organs first.
Exception Points: Certain clinical conditions that carry a high risk of mortality or drop-out but are not fully captured by lab values—such as Hepatocellular Carcinoma (HCC), hepatopulmonary syndrome, or metabolic disorders—may qualify the patient for "MELD/PELD exception points" via institutional transplant board reviews
References:
Kim, W. R., Mannalithara, A., Heimbach, J. K., et al. (2021). MELD 3.0: The Model for End-Stage Liver Disease Updated for the Current Era. Gastroenterology, 161(6), 1887-1895.
Organ Procurement and Transplantation Network (OPTN). (2023). Update to PELD to Include Creatinine (PELD-Cr). Policy Notice, Health Resources and Services Administration (HRSA).
Kamath, P. S., & Kim, W. R. (2007). The Model for End-Stage Liver Disease (MELD). Hepatology, 45(3), 797-805.
Got any Suggestion?
Contact:
info@histamind.com